Ruxolitinib Cream in Adolescents/Adults with Atopic Dermatitis Meeting Severity Thresholds for Systemic Therapy: Exploratory Analysis of Pooled Results from Two Phase 3 Studies

Ruxolitinib Cream in Adolescents/Adults with Atopic Dermatitis Meeting Severity Thresholds for Systemic Therapy: Exploratory Analysis of Pooled Results from Two Phase 3 Studies

Abstract Introduction Standard therapy for patients with mild to moderate atopic dermatitis (AD) typically includes topical therapies; however, patients with more extensive AD and/or AD refractory to topical therapy may benefit from systemic treatment. Ruxolitinib cream monotherapy has demonstrated...

Full description

Bibliographic Details
Main Authors: Eric L. Simpson, Leon Kircik, Andrew Blauvelt, Howard Kallender, Daniel Sturm, Mingyue Wang, Lawrence F. Eichenfield
Format: Article
Language:English
Published: Adis, Springer Healthcare 2024-07-01
Series:Dermatology and Therapy
Subjects:
Atopic dermatitis
Ruxolitinib cream
Janus kinase inhibition
JAK
Online Access:https://doi.org/10.1007/s13555-024-01219-8

Internet

https://doi.org/10.1007/s13555-024-01219-8

Similar Items